IB ACQUISITION CORP.

IBAC ·Healthcare, Diagnostics & Research, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2025 FY2024 FY2023
Revenue
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development
SG&A Expense $748.9K $524.0K $6.8K
Operating Income $-748.9K $-524.0K $-6.8K
Operating Margin
Interest Expense
Pretax Income $4.4M $2.5M $-6.8K
Income Tax Expense $965.6K $635.5K
Net Income $3.4M $1.9M $-6.8K
Net Margin
EPS (Basic)
EPS (Diluted)
Shares Outstanding (Basic) 5.7M 15.7M 3.2M
Shares Outstanding (Diluted) 5.7M 15.7M 3.2M
Dividends Per Share